vitiligo
Conditions
Interventions
Treatment group:Uyghur medicine for internal and external use + medicinal bath + fumigation treatment + fire needle treatment + laser treatment
Sponsors
Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) The diagnosis of progressive vitiligo was consistent with VIDA score > 1; (2) Patients with vitiligo severity rated as grade 1 (mild, unlimited in special parts, =0.09% white spot area in other parts (3 knuckles)), grade 2 (moderate, 1%-5% white spot area), grade 3 (moderate and severe, 6%-50% white spot area), and grade 4 (severe, > 50% white spot area); (3) It is consistent with the diagnosis of non-segmental (ordinary) vitiligo, including sporadic, generalized and mixed type; (4) Uyghur patients with vitiligo whose syndrome is astringent mucous type; (5) Ages 18-65; 6) Informed consent, voluntary testing.
Exclusion criteria
Exclusion criteria: (1) Patients with vitiligo in special parts such as external genitalia, anus and mucosa; (2) Some rashes after the disappearance of pigment, anemia nevus, albinism, and other syndromes caused white spots, senile white spots, anochromic nevus, solar white spots, etc.; (3) Patients with active tuberculosis, advanced malignant tumor or tumor history within 5 years; (4) Combined with serious heart dysfunction, liver, kidney system and other serious primary diseases. (Note: ALT and AST exceed the upper limit of the normal range by 2 times, Cr exceeds the upper limit of the normal range.) ; (5) have taken steroid drugs in the last 2 weeks, and have taken any drug to treat vitiligo; And/or have taken retinoids or topical steroids and any topical medication for vitiligo within 1 week; (6) Women planning pregnancy, pregnancy or breastfeeding; (7) Suspected or have a history of alcohol and drug abuse; (8) Allergic constitution (to more than 2 other drugs), or allergic to the drug ingredients in this diagnosis and treatment plan; (9) Those who have other conditions that reduce the possibility of enrollment or complicate enrollment, such as frequent changes in the working environment, mental disorders, communication difficulties, etc., which the researchers deem inappropriate to participate in the clinical trial; (10) Participants who have participated in other drug clinical studies or are participating in other clinical trials within the past 1 month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vitiligo Area Score Index; | — |
Secondary
| Measure | Time frame |
|---|---|
| Uyghur medical syndrome score;Dermatology Life Quality Index;Stable condition at week 12;After-effect of 24 weeks; | — |
Countries
China
Contacts
Public ContactWeiwen Chen
Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
Outcome results
None listed